A real-world analysis presented at the 2026 Meeting of the European Association for the Study of Diabetes in Milan found that people who switched from an injectable GLP-1 medication to the oral semaglutide pill kept losing weight. The OCTANE study is among the first real-world looks at what happens after that switch, and its results have not yet been published in a peer-reviewed journal.

The drugs involved are semaglutide, sold as Wegovy in both injectable and pill form, and tirzepatide, sold as Zepbound. Both are used for weight management in people with overweight or obesity, and the question here is what happens when the needle is swapped for a tablet.

Key results

This was a retrospective cohort analysis of a random sample of 194 adults with overweight or obesity and at least one obesity-related complication such as hypertension, cardiovascular disease, obstructive sleep apnea or dyslipidemia. Average baseline weight was 221.6 pounds and average BMI was 34.5, with no history of diabetes or bariatric surgery.

After three months on oral semaglutide, participants had lost an average of 4.1% of their body weight, or 8.8 pounds. Two in five (40.7%) had lost 5% or more, and the share with a BMI of 30 or above fell 21.6 percentage points, from 87.1% to 65.5%.

Most participants (82.4%) reported at least one treatment improvement, with around 69% citing better-fitting clothes and around 51% saying they ate healthier. Those are self-reported measures, and so were the weights.

Limitations

Real-world data like this does not prove the switch caused the weight loss, and the findings have not cleared peer review. Participants self-reported their weight, there was no requirement for how long they had used an injectable or how much they had already lost, and the follow-up ran only three months.

Betul Hatipoglu, MD, of University Hospitals in Cleveland, who was not involved in the study, told Healthline the results are encouraging but added she would view them as "promising early evidence supporting another treatment option, rather than proof that switching improves results." Mir Ali, MD, of MemorialCare Surgical Weight Loss Center, noted that less of the oral drug reaches the bloodstream, and that studies show the injectable form is more efficacious.

The convenience trade-off

The pill travels well and needs no refrigeration, which is a genuine advantage. It also has to be taken in the morning on an empty stomach with a 30-minute wait before eating, and Hatipoglu says gastrointestinal side effects including nausea, vomiting, diarrhea and constipation are not eliminated by swallowing rather than injecting.

Still waiting on peer review

Until the OCTANE data is published and tested, this is a conference poster describing what happened to 194 people over three months. It is a reasonable first signal that an oral option can hold the line, and nothing more than that yet.